Editorial Commentary


Bladder organoids: a step towards personalised cancer therapy?

Sreemoti Banerjee, Jennifer Southgate

Abstract

Urothelial bladder cancer (UBC) is complicated by its underlying genetic diversity that renders prognosis and treatment a challenge and imposes a significant health and economic burden. Although the non-muscle invasive form of bladder cancer (NMIBC) is responsive to treatment, a significant proportion of tumors recur and patients require lifelong monitoring to identify cancers that become muscle-invasive. Most patients with muscle-invasive bladder cancer (MIBC) present late and show poor response to therapy, with attendant poor survival. This underpins the clinical need for progress in bladder cancer research and translation.

Download Citation